CMSC: Consortium of Multiple Sclerosis Centers
Conference Coverage
Expert: Don’t discourage pregnancy in MS patients; manage it
Conference Coverage
VIDEO: Cannabis further compromises cognitive function in some MS patients
Conference Coverage
No new safety concerns seen in combination treatment with dimethyl fumarate
Key clinical point: Oral delayed-release DMF added to either interferon-beta or glatiramer acetate had adverse event rates similar to those of...
Conference Coverage
Low immunogenicity rates support peginterferon in MS
Key clinical point: The development of antibodies against PEG-INF beta-1a was low and had no discernible impact on safety or tolerability.Major...
Conference Coverage
VIDEO: Helping MS patients regain use of their limbs
Conference Coverage
Prospective studies needed to compare MS in African Americans and whites
Conference Coverage
Copaxone lipoatrophy far more common than reported
Key clinical point: The rate of lipoatrophy with glatiramer acetate may be much higher than reported in the drug’s label.Major finding: Of 73...
Conference Coverage
When switching from natalizumab to teriflunomide, timing is key
Key clinical point: Make the switch as soon as possible – no more than 4 weeks from the last natalizumab infusion – and then monitor the patient...
Conference Coverage
Aquatic therapy deemed beneficial for MS patients
Key clinical point: An aquatic exercise regimen may benefit many areas of life for patients with MS without adverse effects.Major finding: In a...
Conference Coverage
MS experts battle over alemtuzumab’s value
Conference Coverage
VIDEO: Vitamin D helps with optic neuritis, too
Conference Coverage
VIDEO: What’s known so far about plasma exchange in MS, neuromyelitis optica
Conference Coverage
Switching from natalizumab to fingolimod or injectables increased MS disability
Key clinical point: MS patients and physicians should discuss the pros and cons of abandoning natalizumab before switching to fingolimod or...